Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.21.2
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
May 02, 2021
Dec. 21, 2020
Aug. 12, 2020
Sep. 12, 2018
Aug. 20, 2018
Mar. 22, 2018
Sep. 14, 2015
Sep. 14, 2015
Dec. 24, 2013
Dec. 24, 2013
Sep. 30, 2021
Aug. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Loss Contingencies [Line Items]                                
Research and development costs                         $ 227,181 $ 799,420 $ 933,122 $ 1,012,038
General and administrative costs                         1,010,539 802,273 3,762,373 1,350,201
GEIS [Member]                                
Loss Contingencies [Line Items]                                
Amount related to milestone payment                     $ 67,582          
NDA Consulting Corp [Member]                                
Loss Contingencies [Line Items]                                
Agreement term                 one-year periods              
Consulting and advisory fee                   $ 4,000     4,000 4,000 12,000 12,000
City of Hope [Member]                                
Loss Contingencies [Line Items]                                
Aggregate commitments expected                     319,000   319,000   319,000  
City of Hope [Member] | Health Care, Patient Service [Member]                                
Loss Contingencies [Line Items]                                
Aggregate commitments expected                     800,000   800,000   800,000  
Collaboration Agreement [Member]                                
Loss Contingencies [Line Items]                                
Advance amount related to milestone payment                         0 0 24,171 43,411
Research and development costs                             155,053  
Collaboration Agreement [Member] | GEIS [Member]                                
Loss Contingencies [Line Items]                                
Aggregate commitments expected                     4,348,000   4,348,000   4,348,000  
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                                
Loss Contingencies [Line Items]                                
Consulting and advisory fee             $ 10,000                  
Reimbursed expense                         30,000 30,000 90,000 90,000
Stock options grant date fair value               $ 670,715                
Collaboration Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                
Loss Contingencies [Line Items]                                
Advance amount related to milestone payment                         0 10,643 17,693 36,008
Research and development costs                             $ 103,927  
Clinical Trial Agreement [Member]                                
Loss Contingencies [Line Items]                                
Aggregate commitments expected, description                             The Company’s aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $4,950,000 as of September 30, 2021, consisting of approximately $4,348,000 relating to the GEIS clinical trial and approximately $602,000 relating to the Moffit clinical trial, which are expected to be incurred through December 31, 2025.  
Aggregate commitments expected                     4,950,000   4,950,000   $ 4,950,000  
Clinical Trial Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                
Loss Contingencies [Line Items]                                
Aggregate commitments expected                     602,000   602,000   602,000  
Clinical Trial Agreement [Member] | City of Hope [Member]                                
Loss Contingencies [Line Items]                                
Advance amount related to milestone payment                         0   309,509  
Research and development costs                             309,509  
Aggregate commitments expected                     2,433,000   2,433,000   2,433,000  
Other Clinical Agreements [Member]                                
Loss Contingencies [Line Items]                                
Aggregate commitments expected                     394,000   394,000   394,000  
Other Clinical Agreements [Member] | Minimum [Member]                                
Loss Contingencies [Line Items]                                
Research and development costs                             977,000  
Work Order Agreement [Member]                                
Loss Contingencies [Line Items]                                
Research and development costs                             91,505  
Aggregate commitments expected                     868,000   868,000   868,000  
Work Order Agreement [Member] | City of Hope [Member]                                
Loss Contingencies [Line Items]                                
Advance amount related to milestone payment                         6,857   21,170  
Aggregate commitments expected                     $ 21,170   21,170   21,170  
Work Order Agreement [Member] | Theradex Systems, Inc. [Member]                                
Loss Contingencies [Line Items]                                
Research and development costs       $ 954,000                 869 917 9,350 12,393
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Development Milestones [Member]                                
Loss Contingencies [Line Items]                                
Milestone payments           $ 1,750,000                    
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Commercial Milestones [Member]                                
Loss Contingencies [Line Items]                                
Milestone payments           $ 6,500,000                    
Exclusive License Agreement [Member]                                
Loss Contingencies [Line Items]                                
Amount charges to operations                         6,301 $ 6,301 18,698 $ 18,699
Exclusive License Agreement [Member] | First Four Years [Member]                                
Loss Contingencies [Line Items]                                
Minimum payments for royalties                             50,000  
Exclusive License Agreement [Member] | Five Years And Thereafter [Member]                                
Loss Contingencies [Line Items]                                
Minimum payments for royalties                             100,000  
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                
Loss Contingencies [Line Items]                                
Non-refundable license issue fee         $ 25,000                      
Annual license maintenance fee         25,000                      
Payments on non-refundable milestone         $ 1,897,000                      
Percentage of milestone         40.00%                      
Employment Agreement [Member] | Dr. John Kovach [Member]                                
Loss Contingencies [Line Items]                                
Annual salary                       $ 640,000        
Employment Agreement [Member] | Dr.James [Member]                                
Loss Contingencies [Line Items]                                
Annual compensation $ 775,000                              
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member]                                
Loss Contingencies [Line Items]                                
Percentage of proceeds agree to pay under agreement     500.00%                          
Maximum amount received under agreement     $ 250,000                          
Service Agreement [Member] | IRTH Communications, LLC [Member]                                
Loss Contingencies [Line Items]                                
Consulting and advisory fee   $ 7,500                            
Stock options grant date fair value   $ 100,000                            
General and administrative costs                         $ 22,500   $ 67,500